G Leone

Summary

Affiliation: Catholic University
Country: Italy

Publications

  1. ncbi Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies
    Giuseppe Leone
    Institute of Hematology and Institute of cardiology, Catholic University, Rome, Italy
    Curr Med Chem Cardiovasc Hematol Agents 2:311-26. 2004
  2. ncbi Incidence and susceptibility to therapy-related myeloid neoplasms
    Giuseppe Leone
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Largo A Gemelli 8, 00168 Rome, Italy
    Chem Biol Interact 184:39-45. 2010
  3. ncbi Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects
    G Leone
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Largo Gemelli 8, 00168 Rome, Italy
    Cardiovasc Hematol Agents Med Chem 4:33-52. 2006
  4. ncbi Therapy-related myeloid neoplasms
    Giuseppe Leone
    Istituto di Ematologia, Universita Cattolica S Cuore, Rome, Italy
    Curr Opin Oncol 23:672-80. 2011
  5. ncbi Therapy-related leukemia and myelodysplasia: susceptibility and incidence
    Giuseppe Leone
    Istituto di Ematologia, Universita Cattolica S Cuore, L go A Gemelli, 1, 00168 Rome, Italy
    Haematologica 92:1389-98. 2007
  6. ncbi DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias
    Giuseppe Leone
    Institute of Hematology, Catholic University, Rome, Italy
    Haematologica 87:1324-41. 2002
  7. ncbi Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias
    Giuseppe Leone
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Rome, Italy
    Curr Med Chem 15:1274-87. 2008
  8. ncbi Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS
    Giuseppe Leone
    Institute of Hematology, Catholic University, Rome, Italy
    Clin Immunol 109:89-102. 2003
  9. ncbi Blood cells diseases and thrombosis
    G Leone
    Istituto di Ematologia, Universita Cattolica, Largo Gemelli 8, 00168 Rome, Italy
    Haematologica 86:1236-44. 2001
  10. ncbi Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomiz
    L Pierelli
    Cattedra di Ematologia, Istituto di Ostetricia e Ginecologia, Universita Cattolica del Sacro Cuore, Rome, Italy
    J Clin Oncol 17:1288. 1999

Collaborators

Detail Information

Publications147 found, 100 shown here

  1. ncbi Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies
    Giuseppe Leone
    Institute of Hematology and Institute of cardiology, Catholic University, Rome, Italy
    Curr Med Chem Cardiovasc Hematol Agents 2:311-26. 2004
    ....
  2. ncbi Incidence and susceptibility to therapy-related myeloid neoplasms
    Giuseppe Leone
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Largo A Gemelli 8, 00168 Rome, Italy
    Chem Biol Interact 184:39-45. 2010
    ..In solid tumors, treatment for breast cancer and germ-cell tumors has been associated with a 1-5% lifetime risk of t-MN...
  3. ncbi Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects
    G Leone
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Largo Gemelli 8, 00168 Rome, Italy
    Cardiovasc Hematol Agents Med Chem 4:33-52. 2006
    ..Rituximab may cause tumour lysis syndrome. Alemtuzumab causes immunosuppression, increasing the risk of infection. GO may cause hepatotoxicity...
  4. ncbi Therapy-related myeloid neoplasms
    Giuseppe Leone
    Istituto di Ematologia, Universita Cattolica S Cuore, Rome, Italy
    Curr Opin Oncol 23:672-80. 2011
    ....
  5. ncbi Therapy-related leukemia and myelodysplasia: susceptibility and incidence
    Giuseppe Leone
    Istituto di Ematologia, Universita Cattolica S Cuore, L go A Gemelli, 1, 00168 Rome, Italy
    Haematologica 92:1389-98. 2007
    ..In all cases the risk of t-MDS/AML drops sharply by 10 years after treatment...
  6. ncbi DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias
    Giuseppe Leone
    Institute of Hematology, Catholic University, Rome, Italy
    Haematologica 87:1324-41. 2002
    ..DNA methylation abnormalities have recently emerged as the most frequent molecular changes in hematopoietic neoplasms...
  7. ncbi Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias
    Giuseppe Leone
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Rome, Italy
    Curr Med Chem 15:1274-87. 2008
    ..However, studies on leukemias have provided paradigmatic examples for the functional implications of the epigenetic alterations in cancer development and progression as well as their relevance for therapeutical targeting...
  8. ncbi Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS
    Giuseppe Leone
    Institute of Hematology, Catholic University, Rome, Italy
    Clin Immunol 109:89-102. 2003
    ..Clinical trials are still ongoing, and preliminary data indicate for the first time that the natural history of MDS may be changed by a non-intensive treatment, characterized by an outstanding toxicity profile...
  9. ncbi Blood cells diseases and thrombosis
    G Leone
    Istituto di Ematologia, Universita Cattolica, Largo Gemelli 8, 00168 Rome, Italy
    Haematologica 86:1236-44. 2001
    ..Nevertheless the role of leukocytes and red cells in thrombogenesis is not well established and is probably underestimated...
  10. ncbi Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomiz
    L Pierelli
    Cattedra di Ematologia, Istituto di Ostetricia e Ginecologia, Universita Cattolica del Sacro Cuore, Rome, Italy
    J Clin Oncol 17:1288. 1999
    ....
  11. ncbi High cyclin-dependent kinase inhibitors in Bcl-2 and Bcl-xL-expressing CD34+-proliferating haematopoietic progenitors
    M Marone
    Department of Obstetrics and Gynecology and Department of Haematology, Catholic University, Rome, Italy
    Br J Haematol 110:654-62. 2000
    ..Thus, bright cells, despite having a higher proliferation rate than the starting d 0 CD34+ population, have strikingly elevated levels of cyclin-dependent kinase inhibitors, which are likely to also act as inhibitors of differentiation...
  12. ncbi Immune reconstitution after autologous peripheral blood progenitor cell transplantation: effect of interleukin-15 on T-cell survival and effector functions
    S Rutella
    Department of Hematology, Catholic University Medical School, Rome, Italy
    Exp Hematol 29:1503-16. 2001
    ....
  13. ncbi CD34+/CD105+ cells are enriched in primitive circulating progenitors residing in the G0 phase of the cell cycle and contain all bone marrow and cord blood CD34+/CD38low/- precursors
    L Pierelli
    Cattedra di Ematologia Istituto di Ostetricia e Ginecologia, Universita Cattolica del Sacro Cuore, Roma, Italy
    Br J Haematol 108:610-20. 2000
    ..Extensive characterization of these CD105+ precursors indicated that they have biological properties associated with primitive haematopoietic precursors...
  14. ncbi Peripheral blood progenitor cell collection after epirubicin, paclitaxel, and cisplatin combination chemotherapy using EPO-based cytokine regimens: a randomized comparison of G-CSF and sequential GM-/G-CSF
    A Perillo
    Istituto di Ginecologia e Ostetricia, Cattedra di Ematologia, Servizio Trasfusionale, Universita Cattolica del Sacro Cuore, Rome, Italy
    Transfusion 41:674-80. 2001
    ..The peripheral blood progenitor cell (PBPC) mobilization capacity of EPO in association with either G-CSF or sequential GM-CSF/G-CSF was compared in a randomized fashion after epirubicin, paclitaxel, and cisplatin (ETP) chemotherapy...
  15. ncbi High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration
    P Benedetti Panici
    Istituto di Ostetricia e Ginecologia, Catholic University, Rome, Italy
    Br J Cancer 75:1205-12. 1997
    ..Low non-haematological toxicity and accelerated haematopoietic recovery renders CEM with PBPC/growth factor support an acceptable therapeutic approach in an adjuvant or neoadjuvant setting...
  16. ncbi The role of growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation in the treatment of solid tumors: results from a randomized comparison of G-CSF and GM-CSF
    L Pierelli
    Hematology and Hemotransfusion Service, Institute of Obstetrics and Gynecology, Sacred Heart Catholic University, Rome, Italy
    Transfusion 41:1577-85. 2001
    ..On the other hand, the best growth factor regimen to potentiate PBPC-mediated immunohematopoietic recovery has yet to be determined...
  17. ncbi Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation
    L Teofili
    Departments of Hematology, Catholic University, Rome, Italy
    Exp Hematol 28:519-26. 2000
    ..The aim of this study was to investigate whether p15(INK4B) expression is restricted to the granulomonocytic lineage and to evaluate its modulation during normal and leukemic myeloid differentiation...
  18. ncbi In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue
    L Pierelli
    Cattedra di Ematologia, Catholic University, Rome, Italy
    Br J Cancer 78:1024-9. 1998
    ..In conclusion, amifostine protects haematopoietic progenitors from etoposide, carboplatin and taxotere. Progenitor rescue is the mechanism through which amifostine reduced etoposide and carboplatin toxicity...
  19. ncbi Improvement of mortality rate and decrease in histologic hepatic injury after human cord blood stem cell infusion in a murine model of hepatotoxicity
    C Di Campli
    Department of Medical Pathology, Catholic University of Rome, Rome, Italy
    Transplant Proc 37:2707-10. 2005
    ..CONCLUSION: We demonstrated that the infusion of hematopoietic stem cells into the liver in the early stage of damage might initiate endogenous hepatic tissue regeneration that oppose the injury inflicted by toxicants...
  20. ncbi Human cordonal stem cell intraperitoneal injection can represent a rescue therapy after an acute hepatic damage in immunocompetent rats
    A C Piscaglia
    Dept. of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, Italy
    Transplant Proc 37:2711-4. 2005
    ..CONCLUSIONS: Our study demonstrated that hematopoietic stem cells selectively recruited by injured livers can contribute to hepatic regeneration after acute toxic damage in immunocompetent recipients...
  21. ncbi Granulocyte colony-stimulating factor perturbs lymphocyte mitochondrial function and inhibits cell cycle progression
    S Rutella
    Department of Hematology, Catholic University, Rome, Italy
    Exp Hematol 28:612-25. 2000
    ..Whether immune dysfunction will favorably impact on incidence and severity of acute graft vs host disease after allogeneic PBPC transplantation remains to be determined...
  22. ncbi Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease
    F Burzotta
    Department of Cardiology, Catholic University, Rome, Italy
    Eur Heart J 23:26-30. 2002
    ....
  23. ncbi Acute leukemia following a previous malignancy: do acute lymphoid leukemia and acute myeloid leukemia have common risk factors?
    L Pagano
    Department of Hematology, Catholic University, Largo Francesco Vito 1, I 00168 Rome, Italy
    Hematol J 1:329-32. 2000
    ..Assessment was also made of the clinical course, laboratory features and overall outcome of these conditions...
  24. ncbi Long-term immune recovery after CD34+ immunoselected and unselected peripheral blood progenitor cell transplantation: a case-control study
    L Laurenti
    Divisione di Ematologia, Istituto Semeiotica Medica, Universita Cattolica Sacro Cuore, Largo A Gemelli 8, 00168 Rome, Italy
    Haematologica 84:1100-3. 1999
    ..We compared the long term immunologic recovery in two groups of patients submitted to CD34+ PBPCT or unselected autologous peripheral blood progenitor cell transplantation (uPBPCT)...
  25. ncbi Immune reconstitution following transplantation of autologous peripheral CD34+ cells
    S Sica
    Department of Haematology, Catholic University School of Medicine, Rome, Italy
    Acta Haematol 105:179-87. 2001
    ..No differences in the repopulation kinetics of NK cells and CD19+ B cells were observed. Further investigations are encouraged to characterize T cell competence following transplantation of CD34+ PBPC...
  26. ncbi Immune reconstitution after autologous selected peripheral blood progenitor cell transplantation: comparison of two CD34+ cell-selection systems
    L Laurenti
    Department of Haematology, Catholic University School of Medicine, Rome, Italy
    Transfusion 41:783-9. 2001
    ..This procedure seems to delay lymphocyte recovery, while myeloid engraftment is no different from that with unselected PBPC transplants...
  27. ncbi The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment
    V De Stefano
    Institute of Hematology, Catholic University, Rome, Italy
    J Thromb Haemost 3:1985-92. 2005
    ..Yet, most reports are anecdotical and scarce data are available on the risk of thrombosis in acute myeloid leukemia (AML)...
  28. ncbi Autologous graft-versus-host disease after CD34+-purified autologous peripheral blood progenitor cell transplantation
    S Sica
    Istituto di Semeiotica Medica Divisione Ematologia, Universita Cattolica Sacro Cuore, Rome, Italy
    J Hematother Stem Cell Res 9:375-9. 2000
    ..These observations add new interest to the antitumor efficacy of autologous GVHD and suggest new questions regarding the role of transplantation for autoimmune diseases...
  29. ncbi Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia
    P Chiusolo
    Department of Hematology, , Rome, Italy
    Exp Hematol 29:670-6. 2001
    ..Clonal hemopoiesis is easily recognized by X-CIP, but its applicability is limited to the female sex and is hampered by the presence of age-related or constitutive skewing...
  30. ncbi Transplantation of autologous peripheral blood progenitor cells: impact of CD34-cell selection on immunological reconstitution
    S Rutella
    Department of Hematology, Catholic University Medical School, Rome, Italy
    Leuk Lymphoma 42:1207-20. 2001
    ....
  31. ncbi Telomerase activity in human hematopoietic progenitor cells
    S Hohaus
    Department of Medical Genetics, Universita Cattolica S Cuore, Rome, Italy
    Haematologica 82:262-8. 1997
    ..Recently, telomerase activity has been observed in human bone marrow (BM) and peripheral blood (PB) samples. The objective of our study was to further characterize the telomerase-expressing population in BM and PB...
  32. ncbi Stem cell collection using the dideco excel continuous flow blood cell separator: parameters for optimal stem cell collection timing
    M Lai
    Chair of Hematology, Universita Cattolica del Sacro Cuore, Roma, Italy
    Int J Artif Organs 23:703-9. 2000
    ..5x10(6)/kg CD34+ cells with a single procedure in 68.8% of patients and assuring complete recovery after stem cell transplantation...
  33. ncbi Caspofungin for the treatment of candidaemia in patients with haematological malignancies
    L Pagano
    Haematology and Microbiology Institutes, Catholic University, Rome, Italy
    Clin Microbiol Infect 16:298-301. 2010
    ..These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups...
  34. ncbi Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome
    Ida Casorelli
    Istituto Superiore di Sanita, Laboratorio di Tossicologia Comparata, Rome, Italy
    DNA Repair (Amst) 2:547-59. 2003
    ..In view of the established relationship between drug resistance and mismatch repair defects, we suggest that selection for therapeutic drug resistance may contribute to the incidence of MSI(+) tAL/MDS...
  35. ncbi PCR-restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies
    G Morace
    Institutes of Microbiologia, Facoltà di Medicina e Chirurgia A Gemelli, Universita Cattolica del Sacro Cuore, 1 00168 Rome, Italy
    J Clin Microbiol 37:1871-5. 1999
    ..The molecular method is significantly more sensitive than conventional fungal blood cultures and has a high negative predictive value (97.5%) for the development of disseminated candidiasis in neutropenic patients...
  36. ncbi Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia
    M T Voso
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Rome, Italy
    Leukemia 22:1685-91. 2008
    ..003 and 0.03, respectively), whereas GSTT1 and GSTM1 genotypes had no significant impact. The favorable impact of GSTP1(*)105 Val on RFS seems to be restricted to the subgroup of patients exhibiting a normal karyotype...
  37. ncbi Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia
    L Fianchi
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Roma, Italy
    Ann Oncol 19:128-34. 2008
    ..We evaluated efficacy and safety of a chemotherapy including growth factors, cytarabine, and GO (G-AraMy) in the treatment of poor-prognosis AML in elderly patients...
  38. ncbi Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation
    Valerio De Stefano
    Institute of Hematology, Catholic University, Largo Gemelli 8, 00168, Rome, Italy
    Ann Hematol 89:141-6. 2010
    ..15, 95% CI 1.51-24.92). In conclusion, a homozygous JAK2 V617F mutation is an independent risk factor for recurrent thrombosis in patients with ET...
  39. ncbi Induction of CD69 antigen on normal CD4+ and CD8+ lymphocyte subsets and its relationship with the phenotype of responding T-cells
    S Rutella
    Department of Hematology, Catholic University, Rome, Italy
    Cytometry 38:95-101. 1999
    ....
  40. ncbi Molecular and clinical follow-up after stem cell transplantation for multiple myeloma
    P Chiusolo
    Istituto di Semeiotica Medica, Divisione di Ematologia, Universita Cattolica del Sacro Cuore, Rome, Italy
    Ann Hematol 80:90-5. 2001
    ..Another patient died 4 months after transplantation after succumbing to fatal pneumonia showing myeloma progression...
  41. ncbi Rescue therapy by portal infusion of autologous stem cells in a case of drug-induced hepatitis
    A Gasbarrini
    Department of Medical Pathology, Catholic University of Rome, Largo Gemelli 1, 00168 Rome, Italy
    Dig Liver Dis 39:878-82. 2007
    ..Intrahepatic injection of peripheral-blood stem cells seemed safe and produced good periprocedural results with improvement of synthetic profile, suggesting a possible role of stem cells in the regeneration process...
  42. ncbi Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis
    Stefan Hohaus
    Istituto di Ematologia, Universita Cattolica S Cuore, 00168 Rome, Italy
    Clin Cancer Res 9:3435-40. 2003
    ....
  43. ncbi Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas
    S Hohaus
    Istituto di Ematologia e di Anatomia Patologica, Universita Cattolica S Cuore, Rome, Italy
    Ann Oncol 20:1408-13. 2009
    ..Levels of cell-free circulating DNA have been correlated to clinical characteristics and prognosis in patients with cancers of epithelial origin, while there are no data on patients with B-lymphoproliferative diseases...
  44. ncbi Lymphoid blastic crisis in Philadelphia chromosome-positive chronic granulocytic leukemia following high-grade non-Hodgkin's lymphoma A case report and review of literature
    L Mele
    Istituto di Semeiotica Medica, Universita Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy
    Haematologica 85:544-8. 2000
    ..This is the first case, described in literature, of a secondary chronic granulocytic leukemia onset with a lymphoid blastic crisis. The authors report the case and a literature review...
  45. ncbi G20210A prothrombin gene polymorphism and coronary ischaemic syndromes: a phenotype-specific meta-analysis of 12 034 subjects
    F Burzotta
    Institute of Cardiology, Catholic University, Rome, Italy
    Heart 90:82-6. 2004
    ..To investigate the possible link between the G20210A prothrombin gene variant and different forms of ischaemic heart disease...
  46. ncbi Kinetics of peg-filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplantation
    N Piccirillo
    1Haematology Institute, A Gemelli Hospital, Catholic University, Rome, Italy
    Bone Marrow Transplant 40:579-83. 2007
    ..Duration of antibiotic therapy was significantly shortened, but we did not observe significant differences in other end points. In conclusion, peg-filgrastim was well tolerated and efficacious, and hastened myeloid recovery...
  47. ncbi Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes
    M T Voso
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Roma, Italy
    Ann Oncol 18:1523-8. 2007
    ..Polymorphisms in genes involved in detoxification and DNA-repair pathways may modify the individual's risk for genomic damage, and, as a consequence, the risk of developing malignant diseases...
  48. ncbi Primary plasma cell leukemia: a retrospective multicenter study of 73 patients
    L Pagano
    Institute of Hematology, Catholic University, Rome
    Ann Oncol 22:1628-35. 2011
    ..Epidemiological and clinical information on primary plasma cell leukemia (pPCL) are rarely reported. The aims are to evaluate the clinical features, prognostic factors, and efficacy of treatments in pPCL...
  49. ncbi Acute myeloid leukemia in patients previously diagnosed with breast cancer: experience of the GIMEMA group
    L Pagano
    epartment of Haematology, Catholic University, Roma, Italy
    Ann Oncol 12:203-7. 2001
    ....
  50. ncbi Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes
    Emiliano Fabiani
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, L go A Gemelli, Rome, Italy
    Leuk Res 33:1068-71. 2009
    ..R. 1.66; p=0.04) and to higher probability of overall survival in the low/intermediate-1 IPSS risk group (p=0.008). The GSTP1-Ile105Val polymorphism is likely to influence MDS risk and prognosis...
  51. ncbi The role of bronchoalveolar lavage in the microbiological diagnosis of pneumonia in patients with haematological malignancies
    L Pagano
    Istituto di Semeiotica Medica, Universita Cattolica del Sacro Cuore, Rome, Italy
    Ann Med 29:535-40. 1997
    ....
  52. ncbi Bax mutations are an infrequent event in indolent lymphomas and in mantle cell lymphoma
    M Martini
    Istituto di Anatomia Patologica, Policlinico Gemelli, Universita Cattolica del Sacro Cuore, L go F Vito 1, 00168, Rome, Italy
    Haematologica 85:1019-23. 2000
    ..Recently, it has been proposed that inactivating mutations of this death agonist may contribute to the pathogenesis of human tumors. This study was aimed at defining the status of the Bax gene in indolent lymphomas...
  53. ncbi CD105 (endoglin) expression on hematopoietic stem/progenitor cells
    L Pierelli
    Istituto di Ostetricia e Ginecologia, Universita Cattolica S Cuore, Roma, Italy
    Leuk Lymphoma 42:1195-206. 2001
    ....
  54. ncbi Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors
    L Teofili
    Institutes of Hematology and Pathology, , Rome, Italy
    Blood 98:495-7. 2001
    ..These findings suggest that p15 methylation occurs in a neoplastic clone with a profound defect of cell proliferation, survival, and differentiation that cannot be overcome by using a demethylating drug...
  55. ncbi High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results
    M G Salerno
    Department of Gynecology, Catholic University of Rome, Rome, Italy
    Bone Marrow Transplant 27:1017-25. 2001
    ..Patients who underwent IDS because of unresectable tumors at the time of first surgery had the greater survival benefit from HDC...
  56. ncbi Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells
    S Gobessi
    ICGEB Molecular Hematology Group, Campus A Buzzati Traverso, Rome, Italy
    Leukemia 23:686-97. 2009
    ....
  57. ncbi The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population
    I Casorelli
    Department of Haematology, Catholic University, Rome, Italy
    Br J Haematol 114:150-4. 2001
    ..We conclude that the GP Ia 807 TT (873 AA) genotype is associated with an increased risk of acute coronary syndrome in the Italian population; conversely, the GP Ia 807 CC (873 GG) genotype seems to represent a protective factor...
  58. ncbi Kinetics of hemopoietic recovery after peripheral blood stem cell transplantation: impact of stem cell purification and G-CSF
    Nicola Piccirillo
    Istituto di Semeiotica Medica, Divisione di Ematologia, , Rome, Italy
    Am J Hematol 69:7-14. 2002
    ..In conclusion, these preliminary data suggest that G-CSF is useful if given early after CD34(+) PBSCT. CD34(+) PBSCT may overall require a significant increase of resource utilization that should be outweighed by proven clinical benefit...
  59. ncbi Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma
    Stefan Hohaus
    Istituto di Ematologia, Universita Cattolica S Cuore, Largo A Gemelli 1, 00168 Rome, Italy
    Clin Cancer Res 11:2175-9. 2005
    ..We assessed the impact of the GSTP1 codon 105 genotype on treatment outcome in patients with Hodgkin's lymphoma...
  60. ncbi Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups
    Sergio Amadori
    Department of Hematology, University Tor Vergata, St Eugenio Hospital, Rome, Italy
    Haematologica 89:950-6. 2004
    ..The aim of this collaborative trial was to assess the feasibility, safety, and antileukemic activity of administering GO followed by conventional chemotherapy as first line therapy in patients aged 61-75 years with AML...
  61. ncbi The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia
    Elena Rossi
    Institute of Hematology, Catholic University, Rome, Italy
    Thromb Haemost 99:1030-4. 2008
    ..7, 95%CI 0.5-1.0) in comparison with those with unknown inherited defect. These data suggest that patients with proximal DVT have different risks of symptomatic PE according to the type of inherited thrombophilia...
  62. ncbi Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia
    Francesco D'Alo
    Istituto di Ematologia, Universita Cattolica S Cuore, Rome, Italy
    Haematologica 89:664-70. 2004
    ..We studied the polymorphisms of cytochrome P450 CYP1A1 and glutathione S-transferase (GST), enzymes involved in the metabolism of carcinogens and anti-cancer drugs, as risk factors for adult AML...
  63. ncbi Different circumstances of the first venous thromboembolism among younger or older heterozygous carriers of the G20210A polymorphism in the prothrombin gene
    Valerio De Stefano
    Institute of Hematology, Catholic University, Rome, Italy
    Haematologica 88:61-6. 2003
    ..The aim of this study was to determine the risk of spontaneous or secondary venous thromboembolism (VTE) among younger and older carriers of the G20210A prothrombin polymorphism...
  64. ncbi Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells
    Sergio Rutella
    Departments of Hematology and Gynecology, Catholic University Medical School, Rome, and the Laboratory of Clinical Pathology and Microbiology, IRCCS San Gallicano, Rome, Italy
    Blood 100:2562-71. 2002
    ..Tr cells generated ex vivo after exposure to G-CSF might be clinically relevant for transplantation medicine and for the treatment of human immune-mediated diseases...
  65. ncbi Screening for inherited thrombophilia: indications and therapeutic implications
    Valerio De Stefano
    Institute of Hematology, Catholic University, Roma, Italy
    Haematologica 87:1095-108. 2002
    ..The most common inherited traits (deficiency in antithrombin, protein C, or protein S, factor V Leiden, prothrombin G20210A) and mild hyperhomocysteinemia are diagnosed in at least 40% of patients with venous thromboembolism (VTE)...
  66. ncbi Therapy related leukemias: susceptibility, prevention and treatment
    G Leone
    Division of Hematology, Catholic University, Rome
    Leuk Lymphoma 41:255-76. 2001
    ..Whenever possible, the exclusion of drugs known to be leukemogenic from the treatment schedules should be considered, especially in young patients...
  67. ncbi Expression of thrombospondin receptor (CD36) in B-cell chronic lymphocytic leukemia as an indicator of tumor cell dissemination
    S Rutella
    Department of Hematology, Center for the Flow Cytometric Study of Blood Cells, Catholic University, Largo A Gemelli 8, 00168 Rome, Italy
    Haematologica 84:419-24. 1999
    ..We investigated the expression of CD36 in B-cell chronic lymphocytic leukemia (CLL) by multiparameter flow cytometry; results were correlated with clinical features...
  68. ncbi No evidence of hematopoietic stem cell mobilization in patients submitted to hepatectomy or in patients with acute on chronic liver failure
    C Di Campli
    Department of Medical Pathology, Hepato-Biliary Surgery Unit, Catholic University of Rome, Rome, Italy
    Transplant Proc 37:2563-6. 2005
    ..Under these circumstances liver regeneration can probably call upon mature hepatocytes and endogenous progenitor cells. The involvement of extrahepatic progenitors if any, is a rare and limited phenomenon...
  69. ncbi Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer
    A Perillo
    Department of Gynaecology and Obstetrics, Catholic University of the Sacred Heart, Rome, Italy
    Bone Marrow Transplant 30:571-8. 2002
    ..020). These results demonstrate that low-dose IL-2 can be safely administered in combination with G-CSF/EPO early after PBSCT and that it exerts favorable effects on post-PBSCT myeloid reconstitution, but not on immune recovery...
  70. ncbi Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells
    Aleksandar Petlickovski
    International Centre for Genetic Engineering and Biotechnology Outstation Monterotondo, Rome, Italy
    Blood 105:4820-7. 2005
    ..These data demonstrate that only sustained BCR signaling can promote survival of CLL B cells and indicate that the main difference between CLL with mutated and unmutated V(H) genes may reside in the availability of such stimulation...
  71. ncbi Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients
    Mariangela Palladino
    Department of Hematology, Universita Cattolica del Sacro Cuore, Rome, Italy
    Acta Haematol 123:230-4. 2010
    ..We conclude that oral administration of valganciclovir can induce clearance of CMV viral load in about 2 weeks; moreover, lower-dose oral valganciclovir (900 mg/day) has a comparable efficacy to the proposed standard dose (1,800 mg/day)...
  72. ncbi HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART
    M B Lucia
    Departments of Infectious Diseases and Hematology, Catholic University, Rome, Italy
    J Acquir Immune Defic Syndr 27:321-30. 2001
    ..This ability may contribute to P-gp efflux function defect found in HIV-infected patients and suggests that drug interaction studies are crucial to an overall understanding of the effects of this important group of drugs...
  73. ncbi Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders
    V De Stefano
    Institute of Hematology, Catholic University, Rome, Italy
    J Thromb Haemost 5:708-14. 2007
    ..The clinical significance of such findings deserves further investigation...
  74. ncbi Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors
    S Rutella
    Department of Hematology Catholic University Medical School Rome, Rome, Italy
    Cytotherapy 5:19-30. 2003
    ....
  75. ncbi NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey
    L Pagano
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Roma
    Ann Oncol 17:794-800. 2006
    ..To evaluate the clinical characteristics and outcome of NK/T-cell lymphoma 'nasal type' developed in Italian patients...
  76. ncbi Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial
    A Mastrofrancesco
    San Gallicano Dermatological Institute, IRCCS, Rome, Italy
    Clin Exp Dermatol 32:631-6. 2007
    ..Vitiligo is an acquired depigmenting disease with uncertain aetiopathogenesis, possibly associated with oxidative stress. Narrowband ultraviolet B phototherapy (NB-UVB) is the most widely used and effective treatment...
  77. ncbi G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome
    Francesco Burzotta
    Institute of Cardiology, Catholic University, Rome, Italy
    Haematologica 89:1134-8. 2004
    ..The prognostic value of the G20210A prothrombin gene polymorphism in patients with a first acute coronary syndrome has not been previously assessed. We conducted a prospective study to investigate this issue...
  78. ncbi Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
    Valerio De Stefano
    Institute of Hematology, Catholic University, Largo Gemelli 8, 00168 Rome, Italy
    Haematologica 93:372-80. 2008
    ..Prior thrombosis is a well-established risk factor for re-thrombosis in polycythemia vera and essential thrombocythemia but scarce data are available on the rate of re-thrombosis and the optimal strategy for prevention of recurrence...
  79. ncbi Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha
    Sergio Rutella
    Department of Hematology, Laboratory of Immunology, Catholic University Medical School, Rome, Italy
    Eur J Immunol 34:1291-302. 2004
    ..This novel mechanism of immune regulation effected by G-CSF might be therapeutically exploited for tolerance induction in autoimmune disorders...
  80. ncbi Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma
    S Hohaus
    Istituto di Ematologia e di Anatomia Patologica, Universita Cattolica S Cuore, Rome, Italy
    Ann Oncol 18:1376-81. 2007
    ..Cytokine expression can be altered by common single nucleotide polymorphisms (SNPs) in the 5'-promoter regions...
  81. ncbi Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne
    L Pagano
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Roma, Italia
    Clin Infect Dis 45:1161-70. 2007
    ....
  82. ncbi The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients
    L Pagano
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Rome, Italy
    Oncogene 26:3679-90. 2007
    ..As for adverse events, veno-occlusive syndrome characterizes its tolerability profile, but GO is comparatively well tolerated by most patients...
  83. ncbi Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate
    P Chiusolo
    Cattedra di Ematologia, Divisione di Ematologia, Università Cattolica Sacro Cuore Roma, Italy
    Ann Oncol 13:1915-8. 2002
    ....
  84. ncbi Fungal pneumonia due to molds in patients with hematological malignancies
    L Pagano
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy
    J Chemother 18:339-52. 2006
    ....
  85. ncbi Phosphatidylserine exposure in platelet concentrates during the storage period: differences between the platelets collected with different cell separators
    M Lai
    Immunohematology Laboratory, Chair of Hematology, Transfusion Center, Catholic University of Sacred Heart, Largo Gemelli 8, Roma 00168, Italy
    Transfus Apher Sci 27:239-45. 2002
    ..We studied the platelet alterations during the storage period in apheresis concentrates, employing flow cytometry for phosphatidylserine (PS) detection on platelets during the five days of storage...
  86. ncbi Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials
    L Pagano
    Cattedra di Ematologia, Universita Cattolica S Cuore, Largo Francesco Vito 1, I 00168 Rome, Italy
    Ann Oncol 16:228-33. 2005
    ..The aim of the study was to evaluate the outcome of acute myeloid leukaemia (AML) in patients with a previous malignancy (sAML) treated with chemo- and/or radiotherapy, enrolled in conventional trials...
  87. ncbi Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia
    L Pagana
    Department of Haematology, Catholic University, Roma, Italia
    Br J Haematol 112:109-17. 2001
    ..4%), P < 0.046] as well as in median CR duration (55 vs. 24 months, P < 0.02). The analysis of our data suggests that not only previous chemotherapy but also genetic predisposition could play a role in the pathogenesis of sAML...
  88. ncbi Clinical and epidemiological features of acute lymphoblastic leukemia following a previous malignancy
    L Pagano
    Cattedra di Ematologia, Universita Cattolica S Cuore, Roma, Italia
    Leuk Lymphoma 39:465-75. 2000
    ..In this review we report data of the current literature on secondary acute lymphoblastic leukemia, both in adults and children, in order to analyze its incidence and clinical and laboratory features...
  89. ncbi New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia
    L Laurenti
    Hematology Department, Catholic University of Sacred Hearth, Largo Agostino Gemelli, 00168 Rome, Italy
    Mini Rev Med Chem 11:508-18. 2011
    ..Nowadays there are several new promising monoclonal antibodies under investigation against the CD20, CD23, CD37 and CD40 molecules. Application of newer monoclonal antibodies represents an area of ongoing clinical research in CLL...
  90. ncbi Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia
    Valerio De Stefano
    The Institute of Hematology, Catholic University, Rome, Italy
    Am J Hematol 85:97-100. 2010
    ..4 x 10(9)/L at the time of the first thrombotic episode. The prognostic role for leukocytosis was age-related, as it was only significant in patients that were aged <60 years (HR for arterial recurrence 3.35, 95% CI 1.22-9.19)...
  91. ncbi Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia
    Valerio De Stefano
    Institute of Hematology, Catholic University, Largo Gemelli 8, 00168 Rome, Italy
    Haematologica 94:733-7. 2009
    ..In conclusion, in the younger patients with ET the thrombotic risk is higher in the JAK2 V617F-mutated and is further increased by the presence of inherited thrombophilia...
  92. ncbi In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin
    Mothanje Barbara Lucia
    Department of Infectious Diseases, Catholic University, Rome, Italy
    J Acquir Immune Defic Syndr 30:369-78. 2002
    ..Moreover, HIV PIs possess an inhibitory effect on P-gp function that may improve DOX sensitivity in KS spindle cells...
  93. ncbi Hema e-Chart: Italian Registry for prospective analysis of epidemiology, management and outcome of febrile events in patients with hematological malignancies
    L Pagano
    Istituto di Ematologia, Universita Cattolica S Cuore, Roma, Italy
    J Chemother 22:20-4. 2010
    ..As enrollment continues, data will be analyzed and published, which will provide valuable information concerning the epidemiology, therapy, and outcome of infectious complications...
  94. ncbi Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome
    Luca Laurenti
    Istituto di Ematologia, Policlinico A Gemelli, Universita Cattolica del Sacro Cuore, Rome, Italy
    Ann Hematol 90:59-65. 2011
    ..We confirm that FC is an effective regimen with mild toxicities; it could be recommended for patients with low-risk biological parameters who represent, in our experience, about 30% of the total...
  95. ncbi MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients
    Patrizia Chiusolo
    Hematology Department, Universita Cattolica del Sacro Cuore, Largo A Gemelli 8, 00168 Rome, Italy
    Leuk Res 31:1669-74. 2007
    ..02). In the same subgroup we confirmed the role of 677TT variant on toxicity during MTX treatment (p=0.003)...
  96. ncbi Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia
    Maria Teresa Voso
    Istituto di Ematologia, Universita Cattolica S Cuore and Dipartmento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza, Rome, Italy
    Blood 100:2703-7. 2002
    ..003). In conclusion, individuals with GSTM1 or GSTT1 deletions (or deletions of both) may have an enhanced resistance to chemotherapy and a shorter survival...
  97. ncbi Epigenetic changes in therapy-related MDS/AML
    Maria Teresa Voso
    Istituto di Ematologia, Universita Cattolica Sacro Cuore, Largo A Gemelli 8, 00168Rome, Italy
    Chem Biol Interact 184:46-9. 2010
    ..However, how the epigenetic machinery is disrupted after chemo/radiotherapy and during secondary carcinogenesis is still unknown, warranting further studies...
  98. ncbi Scedosporiosis in patients with acute leukemia: a retrospective multicenter report
    Morena Caira
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Largo Francesco Vito, I 00168 Rome, Italy
    Haematologica 93:104-10. 2008
    ..New drugs with in vitro activity against Scedosporium spp (voriconazole, posaconazole) should be considered. However, their clinical activity should be more widely demonstrated...
  99. ncbi Early diagnosis followed by front-line autologous peripheral blood stem cell transplantation for patients affected by POEMS syndrome
    Luca Laurenti
    Haematology Institute, Universita Cattolica del Sacro Cuore, Rome, Italy
    Leuk Res 32:1309-12. 2008
    ..In conclusion early diagnosis is crucial to obtain best response and improve clinical outcome...
  100. ncbi MTHFR polymorphisms involved in vitamin B12 deficiency associated with atrophic gastritis
    Mariangela Palladino
    Hematology Department, Catholic University, L go A Gemelli 8, 00168 Rome, Italy
    Biochem Genet 47:645-50. 2009
    ....
  101. ncbi Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration
    Luca Laurenti
    Istituto di Ematologia, Policlinico A Gemelli, Universita Cattolica del Sacro Cuore, Rome, Italy
    Ann Hematol 87:891-8. 2008
    ..The oral combination of fludarabine and cyclophosphamide is an effective, safe, and well-tolerated regimen that, if confirmed with larger series, will be appropriate especially in patients with low risk biological parameters...